Clinical efficacy, safety, and subjective experience based on ePRO in HIV-infected individuals administered Bictegravir/Emtricitabine/Tenofovir Alafenamide in southwest China.

Linghong KongXiaoxin XieYanhua FuLin GanXiaoyan YangShujing MaHai Long

Published in: Immunity, inflammation and disease (2023)

BIC/FTC/TAF reduces the viral load in ART-naïve patients with high viral load as well as ART-experienced patients with residual viremia. The patient's subjective experience was maintained stable after treatment with BIC/FTC/TAF. This study also revealed a very low incidence for BIC/FTC/TAF drug-related side effects.

Keyphrases

hiv infected
antiretroviral therapy
human immunodeficiency virus
sleep quality
case report
risk factors
single cell
drug induced
hepatitis c virus
electronic health record